dc.creator | Pavlidis, P. | en |
dc.creator | Nikolaidis, V. | en |
dc.creator | Gouveris, H. | en |
dc.creator | Papadopoulos, E. | en |
dc.creator | Kekes, G. | en |
dc.creator | Kouvelas, D. | en |
dc.date.accessioned | 2015-11-23T10:45:15Z | |
dc.date.available | 2015-11-23T10:45:15Z | |
dc.date.issued | 2010 | |
dc.identifier | 10.1016/j.ijporl.2009.12.018 | |
dc.identifier.issn | 0165-5876 | |
dc.identifier.uri | http://hdl.handle.net/11615/32108 | |
dc.description.abstract | Objective: The cochleotoxic effects of aminoglycosides, such as amikacin, are well-established. The aim of the present study was to investigate the possible differences in cochleotoxic effects between once-daily administration (ODA) and twice-daily administration (TDA) of amikacin simulating pediatric dosing. Methods: Twenty-one rabbits were used. Seven animals received intramuscularly amikacin once daily (ODA-group) and seven received the drug twice daily (TDA-group), for a total time period of 2 weeks. All the animals were subjected to Distortion Product Otoacoustic Emissions (DPOAEs) every 3 days since beginning of the experiment. The rest 7 animals did not receive any medication and served as controls (Control group). Two measurements (7 and 14 days) were obtained following the cease of drug administration. Results: Reduced cochlear activity (as depicted in the respective reduced DPOAE-amplitudes) compared to the pre-treatment state was found in both ODA- and TDA-groups. Cochlear activity was reduced at a wider range of frequencies (from 593 to 4031 Hz in TDA-group and from 593 to 1093 Hz in ODA-group) and to a higher degree in group B than in group A. Cochlear activity was reduced earlier in ODA-group than in TDA-group. No differences to the pre-treatment state were observed in the control group. Conclusions: The above findings suggest that less frequent administration in higher dose of amikacin is associated with minimal cochleotoxicity. (C) 2010 Elsevier Ireland Ltd. All rights reserved. | en |
dc.source | International Journal of Pediatric Otorhinolaryngology | en |
dc.source.uri | <Go to ISI>://WOS:000276271700007 | |
dc.subject | Ototoxicity | en |
dc.subject | Cochlear | en |
dc.subject | Amikacin | en |
dc.subject | Post-antibiotic effect | en |
dc.subject | Distortion | en |
dc.subject | Product Otoacoustic Emissions | en |
dc.subject | PRODUCT OTOACOUSTIC EMISSIONS | en |
dc.subject | AMINOGLYCOSIDE OTOTOXICITY | en |
dc.subject | HEARING-LOSS | en |
dc.subject | EFFICACY | en |
dc.subject | SINGLE | en |
dc.subject | METAANALYSIS | en |
dc.subject | SAFETY | en |
dc.subject | INFECTIONS | en |
dc.subject | GENTAMICIN | en |
dc.subject | REGIMEN | en |
dc.subject | Otorhinolaryngology | en |
dc.subject | Pediatrics | en |
dc.title | Ototoxicity caused by once- and twice-daily administration of amikacin in rabbits | en |
dc.type | journalArticle | en |